Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations
Authors
Keywords
-
Journal
BLOOD
Volume 123, Issue 10, Pages 1516-1524
Publisher
American Society of Hematology
Online
2014-01-10
DOI
10.1182/blood-2013-07-518381
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
- (2013) Hideki Terai et al. MOLECULAR CANCER RESEARCH
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop
- (2013) K E Ware et al. Oncogenesis
- FGF signaling facilitates postinjury recovery of mouse hematopoietic system
- (2012) M. Zhao et al. BLOOD
- FGF-2 expands murine hematopoietic stem and progenitor cells via proliferation of stromal cells, c-Kit activation, and CXCL12 down-regulation
- (2012) T. Itkin et al. BLOOD
- Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
- (2012) Douglas Hanahan et al. CANCER CELL
- Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma
- (2012) Vipin Yadav et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities
- (2012) M Ren et al. LEUKEMIA
- Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
- (2012) J. M. Gozgit et al. MOLECULAR CANCER THERAPEUTICS
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- (2012) Jorge E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
- (2012) D. Singh et al. SCIENCE
- IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia Development
- (2011) Damien Reynaud et al. CANCER CELL
- Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia
- (2011) Thomas Schmidt et al. CANCER CELL
- BCR-ABL Mutations in Chronic Myeloid Leukemia
- (2011) Thomas Ernst et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
- (2011) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors
- (2011) E Traer et al. LEUKEMIA
- Ligand activation leads to regulated intramembrane proteolysis of fibroblast growth factor receptor 3
- (2011) Catherine R. Degnin et al. MOLECULAR BIOLOGY OF THE CELL
- Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors
- (2010) D K Hiwase et al. LEUKEMIA
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Contribution of bone microenvironment to leukemogenesis and leukemia progression
- (2009) F Ayala et al. LEUKEMIA
- RNAi screen for rapid therapeutic target identification in leukemia patients
- (2009) J. W. Tyner et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now